Does tadalafil shrink the prostate? This is a common question among men considering treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor licensed for both erectile dysfunction and BPH, works by relaxing smooth muscle tissue in the prostate and bladder neck to improve urinary flow. However, it does not reduce prostate size. Understanding how tadalafil differs from other BPH medications is essential for making informed treatment decisions. This article examines the mechanism, efficacy, and limitations of tadalafil in managing prostatic symptoms.

What Is Tadalafil and How Does It Work?

Tadalafil is a prescription medication belonging to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. It was originally developed and licensed for the treatment of erectile dysfunction (ED), marketed under the brand name Cialis, but has since gained approval for additional indications including benign prostatic hyperplasia (BPH).

The primary mechanism of action involves the inhibition of the PDE5 enzyme, which is found in various tissues throughout the body, including the smooth muscle of blood vessels in the penis, lungs, and lower urinary tract. By blocking PDE5, tadalafil increases levels of cyclic guanosine monophosphate (cGMP), a chemical messenger that promotes smooth muscle relaxation and improved blood flow. In the context of erectile function, this enhanced blood flow facilitates the achievement and maintenance of an erection when combined with sexual stimulation.

In the lower urinary tract, tadalafil's effects extend beyond the vascular system. The medication causes relaxation of smooth muscle in the prostate gland, bladder neck, and urethra, which can alleviate urinary symptoms associated with BPH. For BPH treatment, tadalafil is available as a 5 mg once-daily dose, whilst for erectile dysfunction, it is available in both on-demand doses (10 mg or 20 mg) and lower daily doses (2.5 mg or 5 mg).

The medication is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and should only be used under medical supervision following appropriate assessment and diagnosis by a qualified healthcare professional.

Side Effects and Safety Considerations

Like all medications, tadalafil can cause side effects, though not everyone experiences them. The most commonly reported adverse effects include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion. While some side effects may resolve within hours, back pain and muscle aches typically occur 12-24 hours after taking the medication and can persist for up to 48 hours.

More serious but less common side effects require immediate medical attention. These include sudden vision loss or changes in vision (which may indicate non-arteritic anterior ischaemic optic neuropathy), sudden hearing loss or ringing in the ears, and priapism—a prolonged, painful erection lasting more than four hours that constitutes a medical emergency. Patients experiencing chest pain during or after sexual activity should stop and seek urgent medical advice without taking nitrates, as this may indicate cardiovascular complications. Nitrates should generally be avoided for at least 48 hours after taking tadalafil.

Tadalafil is contraindicated in patients taking nitrate medications (such as glyceryl trinitrate for angina) or guanylate cyclase stimulators (such as riociguat) due to the risk of severe, potentially life-threatening hypotension. It should be used with caution in individuals with significant cardiovascular disease, recent stroke or myocardial infarction, severe hepatic impairment, or hypotension. For daily dosing, tadalafil is not recommended if creatinine clearance is below 30 mL/min or in severe hepatic impairment.

Certain medications can affect tadalafil levels: potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase exposure, while strong inducers (e.g., rifampicin) can reduce effectiveness. When used for BPH, combination with alpha-blockers is generally not recommended due to the risk of hypotension.

Patients should inform their GP or prescriber about all medications they are taking, including over-the-counter products and herbal supplements. The NHS recommends avoiding excessive alcohol consumption when taking tadalafil, as this may increase the likelihood of side effects such as dizziness and hypotension. Patients are encouraged to report any suspected side effects via the MHRA Yellow Card Scheme.

Does Tadalafil Shrink the Prostate?

Tadalafil does not shrink the prostate gland. This is an important distinction that patients and healthcare professionals must understand when considering treatment options for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia.

Unlike 5-alpha reductase inhibitors such as finasteride or dutasteride—which work by blocking the conversion of testosterone to dihydrotestosterone (DHT) and can reduce prostate volume by approximately 20-30% over several months—tadalafil does not alter prostate size or affect hormonal pathways involved in prostate growth. Clinical trials have consistently demonstrated that tadalafil treatment does not result in measurable reduction in prostate volume, nor does it significantly affect prostate-specific antigen (PSA) levels.

The therapeutic benefit of tadalafil in BPH stems from its ability to relax smooth muscle tissue in the prostate, bladder neck, and urethra through PDE5 inhibition and increased cGMP levels. This relaxation improves urinary flow and reduces the resistance to urine passage, thereby alleviating bothersome symptoms such as hesitancy, weak stream, frequency, and nocturia. The medication provides symptomatic relief without addressing the underlying prostatic enlargement.

For patients seeking actual reduction in prostate size—particularly those with enlarged prostates (>30 mL) or PSA >1.4 ng/mL—NICE guidelines recommend considering 5-alpha reductase inhibitors, either alone or in combination with alpha-blockers. The choice of treatment should be individualised based on prostate size, symptom severity, patient preferences, and the presence of complications such as recurrent urinary retention or renal impairment. Patients should discuss realistic treatment expectations with their healthcare provider to ensure appropriate therapy selection.

Tadalafil for Benign Prostatic Hyperplasia (BPH)

Tadalafil received regulatory approval from the European Medicines Agency (EMA) and MHRA for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in 2012. The licensed dose for this indication is 5 mg once daily, which may also provide benefit for men with concurrent erectile dysfunction.

Clinical evidence supporting tadalafil's efficacy in BPH comes from several large, randomised controlled trials. These studies demonstrated statistically significant improvements in the International Prostate Symptom Score (IPSS)—a validated questionnaire measuring urinary symptom severity—compared to placebo. Patients typically experience improvements in both voiding symptoms (hesitancy, weak stream, intermittency) and storage symptoms (frequency, urgency, nocturia). The onset of benefit generally occurs within one to two weeks, though maximal effect may take several weeks to manifest.

According to NICE Clinical Knowledge Summaries, tadalafil represents an alternative treatment option for men with moderate to severe LUTS suggestive of BPH, particularly when alpha-blockers (such as tamsulosin or alfuzosin) are contraindicated, not tolerated, or ineffective. It may be especially appropriate for men who also wish to address erectile dysfunction. However, tadalafil is not typically recommended as first-line monotherapy for BPH in the absence of ED. Combination with alpha-blockers for BPH treatment is generally not recommended due to the risk of hypotension.

Tadalafil is not recommended for daily use in patients with severe renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment, and should be used with caution in moderate hepatic impairment.

Patients should be advised that tadalafil provides symptomatic relief rather than disease modification. Regular review is essential to assess treatment response, monitor for adverse effects, and evaluate for complications of BPH. Men should be referred to urology if they experience acute urinary retention, visible haematuria, recurrent urinary tract infections, abnormal digital rectal examination or age-specific raised PSA, evidence of renal impairment, or failure to respond to medical therapy. Patients experiencing sudden inability to pass urine, visible blood in urine, or severe lower abdominal pain should seek urgent medical attention.

Frequently Asked Questions